Literature DB >> 25349826

Clinical characteristics of diabetic patients transferred to korean referral hospitals.

Min Young Oh1, Sang Soo Kim1, In Joo Kim1, In Kyu Lee2, Hong Sun Baek3, Hyoung Woo Lee4, Min Young Chung5.   

Abstract

BACKGROUND: We evaluated the disease profile and clinical management, including the status of both glycemic control and complications, in patients with diabetes who were transferred to referral hospitals in Korea.
METHODS: Patients referred to 20 referral hospitals in Gyeongsangnam/Gyeongsangbuk-do and Jeollanam/Jeollabuk-do with at least a 1-year history of diabetes between January and June 2011 were retrospectively reviewed using medical records, laboratory tests, and questionnaires.
RESULTS: A total of 654 patients were enrolled in the study. In total, 437 patients (67%) were transferred from clinics and 197 (30%) patients were transferred from hospitals. A total of 279 patients (43%) visited higher medical institutions without a written medical request. The main reason for the referral was glycemic control in 433 patients (66%). Seventy-three patients (11%) had received more than one session of diabetic education. Only 177 patients (27%) had been routinely self-monitoring blood glucose, and 146 patients (22%) were monitoring hemoglobin A1c. In addition, proper evaluations for diabetic complications were performed for 74 patients (11%). The most common complication was neuropathy (32%) followed by nephropathy (31%). In total, 538 patients (82%) had been taking oral hypoglycemic agents. A relatively large number of patients (44%) had been taking antihypertensive medications.
CONCLUSION: We investigated the clinical characteristics of diabetic patients and identified specific problems in diabetic management prior to the transfer. We also found several problems in the medical system, which were divided into three medical institutions having different roles in Korea. Our findings suggested that the relationships among medical institutions have to be improved, particularly for diabetes.

Entities:  

Keywords:  Diabetes mellitus; Korea; Referral and consultation

Year:  2014        PMID: 25349826      PMCID: PMC4209353          DOI: 10.4093/dmj.2014.38.5.388

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


  7 in total

1.  The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

Authors:  A F Amos; D J McCarty; P Zimmet
Journal:  Diabet Med       Date:  1997       Impact factor: 4.359

2.  Diabetes and decline in heart disease mortality in US adults.

Authors:  K Gu; C C Cowie; M I Harris
Journal:  JAMA       Date:  1999-04-14       Impact factor: 56.272

Review 3.  Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.

Authors:  Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt
Journal:  Clin Chem       Date:  2005-12-06       Impact factor: 8.327

4.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

5.  Diabetes in America: epidemiology and scope of the problem.

Authors:  M I Harris
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

6.  The epidemiology of diabetes in Korea.

Authors:  Dae Jung Kim
Journal:  Diabetes Metab J       Date:  2011-08-31       Impact factor: 5.376

7.  Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005.

Authors:  Yong Jun Choi; Hyeon Chang Kim; Hee Man Kim; Seok Won Park; Jongoh Kim; Dae Jung Kim
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 17.152

  7 in total
  1 in total

1.  A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.

Authors:  Soree Ryang; Sang Soo Kim; Ji Cheol Bae; Ji Min Han; Su Kyoung Kwon; Young Il Kim; Il Seong Nam-Goong; Eun Sook Kim; Mi-Kyung Kim; Chang Won Lee; Soyeon Yoo; Gwanpyo Koh; Min Jeong Kwon; Jeong Hyun Park; In Joo Kim
Journal:  Diabetes Obes Metab       Date:  2022-06-09       Impact factor: 6.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.